Search clinical trials for: BRAFV600E mutant

Total 647 results

Memorial Sloan Kettering Cancer Center
Novartis; National Comprehensive Cancer Network

Completed

Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation

Melanoma

United States
NYU Langone Health
Celldex Therapeutics

Terminated

Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma

Melanoma

United States
Cancer Institute and Hospital, Chinese Academy...

Unknown

Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

Non Small Cell Lung Cancer | Stage III Non-small-cell Lung Cancer | EGFR Mutation-Related Tumors
Guangdong Association of Clinical Trials

Unknown

Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure

Non-small Cell Lung Cancer

China
Tocagen Inc.

Terminated

A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)

Melanoma | Sarcoma | Lymphoma | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Bladder Cancer | Triple Negative Breast Cancer | IDH1 Mutated Solid Tumors | IDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting)

United States
Immunovative Therapies, Ltd.

Completed

AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer

Colorectal Cancer Metastatic

United States
Addario Lung Cancer Medical Institute

Withdrawn

PDX Models From EGFR Mutant Tumors

Non Small Cell Lung Cancer

United States
Xu jianmin

Completed

Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases

Colorectal Neoplasms

China
University of California, San Francisco
Novartis Pharmaceuticals; American Cancer Society, Inc.

Terminated

Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Dana-Farber Cancer Institute
Astellas Pharma Inc

Terminated

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

Non-Small Cell Lung Cancer | Epidermal Growth Factor Receptor

United States
Sun Yat-sen University

Unknown

Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC (FL-ALTER)

Lung Cancer, Nonsmall Cell

China
Second Affiliated Hospital of Nanchang University
Nanchang University

Unknown

Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis (OWONBNSCLCLM)

Non-small Cell Lung Cancer | EGFR Activating Mutation | Leptomeningeal Metastasis
Heba sabbagh

Completed

The Effect of Brushing With Salvadorapersica (Miswak) Sticks on Salivary Streptococcus Mutants and Plaque Level in Children: A Clinical Trial

Plaque, Dental
Clovis Oncology, Inc.

Terminated

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Non-small Cell Lung Cancer

Korea, Republic of, United States, France, Germany, Netherlands, Australia, Spain, Taiwan, United Kingdom, Italy
Medical University Innsbruck
European Commission

Terminated

GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

France, Austria, Belgium, Germany
Aprea Therapeutics
Jules Bordet Institute

Terminated

A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma

Melanoma

Belgium
Hoffmann-La Roche

Completed

A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma

Malignant Melanoma

United States, Australia
Hoffmann-La Roche

Completed

A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma (BRIM8)

Melanoma

United States, Israel, Italy, Spain, Belgium, United Kingdom, Austria, Czechia, France, Netherlands, New Zealand, Russian Federation, Australia, Canada, Croatia, Portugal, Germany, Ukraine, Switzerland, Argentina, Brazil, Ireland, N... and more
Washington University School of Medicine

Terminated

Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression

Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Carcinoma, Non-Small-Cell-Lung

United States
Clovis Oncology, Inc.
Genentech, Inc.

Terminated

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

Non-small Cell Lung Cancer

United States
Boston University
Corino Therapeutics, Inc.

Completed

Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR)

Transthyretin Amyloidosis | Amyloidosis, Leptomeningeal, Transthyretin-Related

United States
Millennium Pharmaceuticals, Inc.

Terminated

A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)

Allogeneic Hematopoietic Stem Cell Transplantation

United States, Belgium, Sweden, France, Norway
Bayer

Completed

BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

United States, Germany
Clovis Oncology, Inc.

Terminated

TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy (EGFR)

Non-Small Cell Lung Cancer

Korea, Republic of, United States, Spain, Hong Kong, Taiwan, Germany, Italy
University Health Network, Toronto

Completed

Use of Exome Sequence Analysis and Circulating Tumour in Assessing Tumour Heterogeneity in BRAF Mutant Melanoma

Melanoma

Canada
The University of Hong Kong

Unknown

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

NSCLC Stage IV | EGFR Activating Mutation | NSCLC Stage IIIB

Hong Kong
Cancer Institute and Hospital, Chinese Academy...

Unknown

TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC

Non-Small Cell Lung Cancer Metastatic

China
Novartis Pharmaceuticals

Withdrawn

A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)
Hellenic Oncology Research Group

Unknown

Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC

Non Small Cell Lung Cancer

Greece
National Institute of Allergy and Infectious Diseases...

Completed

Safety of Sublingual dmLT for ETEC

Gastroenteritis Escherichia Coli

United States
Jiangsu HengRui Medicine Co., Ltd.
Shanghai Chest Hospital

Unknown

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Chemotherapy Effect | KRAS Gene Mutation | NSCLC Stage IV | PD-1 Antibody
Memorial Sloan Kettering Cancer Center
Incyte Corporation

Completed

Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib

Lung Cancer

United States
Oncolytics Biotech
Montefiore Medical Center

Completed

Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer

KRAS Mutant Metastatic Colorectal Cancer

United States
Memorial Sloan Kettering Cancer Center
Astellas Pharma US, Inc.

Completed

Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer

EGFR-Mutant Lung Cancer

United States
PATH
International Centre for Diarrhoeal Disease Research, Bangladesh; Scandinavian...

Completed

Enterotoxigenic Escherichia Coli (ETEC) ETVAX Vaccine Trial in Bangladesh (ETVAX/dmLT)

Escherichia Coli Diarrhea

Bangladesh
The Netherlands Cancer Institute
GlaxoSmithKline

Unknown

Lapatinib Plus Trametinib in KRAS Mutant NSCLC (M14LTK)

Colorectal Cancer

Netherlands
The Netherlands Cancer Institute
AstraZeneca; Boehringer Ingelheim

Unknown

Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer (M14AFS)

Gastrointestinal Neoplasms | Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Pancreatic Neoplasms

Netherlands
The Netherlands Cancer Institute
Pfizer

Unknown

Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC (M13DAP)

Colorectal Cancer

Netherlands
Nanfang Hospital of Southern Medical University

Enrolling by invitation

Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML

Acute Myeloid Leukemia | FLT3-ITD Mutation | Brutons Tyrosine Kinase

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer

Non Small Cell Lung Cancer Stage IIIB | EGFR Gene Mutation | Non Small Cell Lung Cancer Stage IIIA

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma (ICWIP)

Adenocarcinoma | EGFR Positive Non-small Cell Lung Cancer

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
Van Andel Research Institute

Withdrawn

Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene

Pancreatic Cancer

United States
Puma Biotechnology, Inc.

Completed

Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer

HER2-mutant Non-Small Cell Lung Cancer

United States, France
Arog Pharmaceuticals, Inc.

Completed

Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene

D842-related Mutant GIST

United States
GlaxoSmithKline
Pfizer

Completed

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors

Cancer

United States
Asan Medical Center

Unknown

Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation

Cancer | Lung Cancer Metastatic | BRAF V600E

Korea, Republic of
Jordan University of Science and Technology

Completed

Antimicrobial Effect of Different Pastes on Streptococcus Mutans in Children

Oral Health | Mutans Streptococci

Jordan
Cascadian Therapeutics Inc.

Terminated

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

Advanced BRAF-mutant Cancers

United States
Boehringer Ingelheim

Completed

Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of, Taiwan, Singapore, Japan
GlaxoSmithKline

Completed

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

Melanoma

United States, Italy, United Kingdom, France, Sweden, Germany, Poland, Australia, Belgium, Austria, Canada, Czechia, Greece, Russian Federation, Ukraine, Norway, Switzerland, New Zealand, Argentina

Search clinical trials for: BRAFV600E mutant

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations